Literature DB >> 24036698

On the validity of time-dependent AUC estimators.

Matthias Schmid, Hans A Kestler, Sergej Potapov.   

Abstract

Recent developments in molecular biology have led to the massive discovery of new marker candidates for the prediction of patient survival. To evaluate the predictive value of these markers, statistical tools for measuring the performance of survival models are needed. We consider estimators of discrimination measures, which are a popular approach to evaluate survival predictions in biomarker studies. Estimators of discrimination measures are usually based on regularity assumptions such as the proportional hazards assumption. Based on two sets of molecular data and a simulation study, we show that violations of the regularity assumptions may lead to over-optimistic estimates of prediction accuracy and may therefore result in biased conclusions regarding the clinical utility of new biomarkers. In particular, we demonstrate that biased medical decision making is possible even if statistical checks indicate that all regularity assumptions are satisfied.
© The Author 2013. Published by Oxford University Press. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  molecular markers; survival analysis; time-dependent AUC

Mesh:

Substances:

Year:  2013        PMID: 24036698     DOI: 10.1093/bib/bbt059

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  4 in total

1.  Boosting the concordance index for survival data--a unified framework to derive and evaluate biomarker combinations.

Authors:  Andreas Mayr; Matthias Schmid
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

2.  Boosting the discriminatory power of sparse survival models via optimization of the concordance index and stability selection.

Authors:  Andreas Mayr; Benjamin Hofner; Matthias Schmid
Journal:  BMC Bioinformatics       Date:  2016-07-22       Impact factor: 3.169

3.  Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling.

Authors:  Loic Yengo; Abdelilah Arredouani; Michel Marre; Ronan Roussel; Martine Vaxillaire; Mario Falchi; Abdelali Haoudi; Jean Tichet; Beverley Balkau; Amélie Bonnefond; Philippe Froguel
Journal:  Mol Metab       Date:  2016-08-23       Impact factor: 7.422

4.  Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.

Authors:  Haider H Samawi; Hao-Wen Sim; Kelvin K Chan; Mohammad A Alghamdi; Richard M Lee-Ying; Jennifer J Knox; Parneet Gill; Adriana Romagnino; Eugene Batuyong; Yoo-Joung Ko; Janine M Davies; Howard J Lim; Winson Y Cheung; Vincent C Tam
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.